Drug Profile


Alternative Names: Debio 9701; DX 890; Engineered protein inhibitor of human neutrophil elastase; EPI-HNE4; Reltran

Latest Information Update: 15 Dec 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dyax
  • Developer Debiopharm; Dyax
  • Class Peptides; Recombinant proteins
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis

Highest Development Phases

  • Discontinued Acute lung injury; Chronic obstructive pulmonary disease; Cystic fibrosis; Respiratory distress syndrome

Most Recent Events

  • 04 May 2006 Preclinical trials in Chronic obstructive pulmonary disease (unspecified route)
  • 04 Jan 2006 Depelestat has been licensed to Debiopharm worldwide for cystic fibrosis and acute respiratory distress syndrome
  • 07 Nov 2005 Phase-I clinical trials in Respiratory distress syndrome in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top